Collapse all
The Business Model Canvas reveals a high-leverage B2B diagnostic model that shifts healthcare from reactive symptom management to proactive homeostasis monitoring. Success depends on integrating with existing clinical laboratory infrastructure and validating a proprietary biomarker panel against established NCD outcomes.
3 Clinical Lab Networks Partnerships with entities like Quest Diagnostics to handle sample processing and distribution of the screening kit. Academic Research Centers Collaboration with endocrinology and oncology departments to refine the biomarker panel for chronodisruption. Health Policy Organizations Working with the WHO to establish global standards for homeostasis-based preventative screening. 3 Biomarker Validation Conducting longitudinal studies to correlate specific neuroendocrine markers with the onset of non-communicable diseases. Diagnostic Assay Development Developing the physical testing kits and the algorithmic scoring system for 'chronodisruption risk'. Clinical Integration Creating software interfaces that allow clinicians to interpret homeostasis data within existing Electronic Health Records (EHR). 3 Proprietary Biomarker IP Patents covering the specific combination of molecular and neuroendocrine markers used to identify chronic stress syndrome. Bioinformatics Pipeline Computational tools used to analyze complex homeostasis data and generate a risk score. Medical Advisory Board Expertise from specialists in chronobiology and systemic inflammation to ensure clinical validity. 3 Early NCD Prediction Identifies systemic vulnerability to cancer and metabolic disorders before clinical symptoms manifest. Homeostasis Quantification Provides a concrete metric for 'chronic stress' that allows for personalized preventative interventions. Reduced Long-term Costs Lowers healthcare spending by preventing the progression of inflammation-driven chronic diseases. 2 B2B Strategic Partnerships Deep integration with health systems like Mayo Clinic to embed the screener into standard preventative check-ups. Clinical Support Providing educational resources and interpretation guides for physicians to act on the screener's results. 3 Diagnostic Lab Integration Distributing the test through established laboratory providers who sell directly to physicians. Medical Conferences Presenting clinical evidence at endocrinology and preventative medicine symposiums to drive adoption. Health System Procurement Direct sales to large hospital networks for use in executive health and longevity programs. 3 Preventative Health Clinics Clinics focused on longevity and early detection of non-communicable diseases. Large-scale Diagnostic Labs Companies like Quest Diagnostics seeking to expand their high-value preventative testing menu. Public Health Agencies Organizations like the WHO implementing population-level health screenings to reduce NCD burdens. 3 R&D and Clinical Trials High initial costs for validating the biomarker panel and securing regulatory approval. Assay Manufacturing Costs associated with producing the chemical reagents and hardware for the screening kits. Regulatory Compliance Expenses related to FDA/EMA certification for a clinical diagnostic tool. 3 Per-Test Licensing Fee A fee paid by diagnostic labs for every Chronodisruption Risk Screen performed. SaaS Analysis Subscription Recurring revenue from clinics using the proprietary software to track patient homeostasis over time. Institutional Licensing Annual flat fees paid by large health systems for enterprise-wide access to the diagnostic tool. Necessary to map how value is delivered to high-profile beneficiaries like the Mayo Clinic and Quest Diagnostics. · Generated 2026-09-07 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated